Literature DB >> 25206067

Non-Hyperammonemic valproate encephalopathy.

Omar Farooq1, Pervaiz M Zunga1, Mohd I Dar1, Abdul Q Rather1, Samia Rashid2, Javid Basu3, Ishrat H Dar4, Mohd Ashraf3.   

Abstract

A 21-year-old male known case of primary hypothyroidism, Seizure disorder sequelae of an old trauma receiving sodium valproate, clobazam and phenobarbitone for control of Generalized tonic clonic seizures reported to neurology OPD with history of altered sensorium and gait unsteadiness for 1 week with history of hike in valproate dose 2 weeks before. On examination he was drowsy. Neurological examination was unremarkable except for gait unsteadiness and ataxia. Patient was admitted and evaluated for acute worsening. All (the) biochemical parameters including complete blood count, liver function tests, kidney function tests, routine urine examination, arterial blood gas analysis, blood and urine culture tests were normal. CSF analysis was also normal. Repeat MRI brain was also done which depicted all old changes with no fresh changes which will account for worsening of his sensorium. EEG was suggestive of diffuse encephalopathy. Thyroid function tests were also normal. Valproate encephalopathy was suspected and Valproate was empirically stopped and he was put on levetiracetam and phenytoin. His sensorium improved rapidly after stoppage of valproate with normalization of EEG. Serum valproate Levels were high with serum ammonia levels were in the normal range. We made the inference of nonhyperammoneamic valproate encephalopathy. This case highlights the existence of non-hyperammonemic valproate induced encephalopathy, suggesting mechanisms other than hyperammonemia responsible for this encephalopathy.

Entities:  

Keywords:  EEG; Hypothyroidism; Valproic acid

Year:  2014        PMID: 25206067      PMCID: PMC4117157          DOI: 10.5214/ans.0972.7531.210210

Source DB:  PubMed          Journal:  Ann Neurosci        ISSN: 0972-7531


  10 in total

1.  Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.

Authors:  H M Hamer; S Knake; U Schomburg; F Rosenow
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

2.  Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy.

Authors:  D L Coulter; R J Allen
Journal:  Lancet       Date:  1980-06-14       Impact factor: 79.321

3.  Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.

Authors:  B S Zaret; R R Beckner; A M Marini; W Wagle; C Passarelli
Journal:  Neurology       Date:  1982-02       Impact factor: 9.910

Review 4.  Drug therapy: Valproic acid.

Authors:  J Koch-Weser; T R Browne
Journal:  N Engl J Med       Date:  1980-03-20       Impact factor: 91.245

5.  Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial status epilepticus.

Authors:  M D Bogdanovic; D Kidd; A Briddon; J S Duncan; J M Land
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

6.  Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.

Authors:  F Barrueto; J B Hack
Journal:  Acad Emerg Med       Date:  2001-10       Impact factor: 3.451

Review 7.  Valproate-induced coma: case report and literature review.

Authors:  J Duarte; S Macias; F Coria; E Fernandez; L E Clavería
Journal:  Ann Pharmacother       Date:  1993-05       Impact factor: 3.154

8.  Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.

Authors:  K Iinuma; K Hayasaka; K Narisawa; K Tada; K Hori
Journal:  Eur J Pediatr       Date:  1988-12       Impact factor: 3.183

9.  Stuporous episodes during treatment with sodium valproate: report of seven cases.

Authors:  C Marescaux; J M Warter; G Micheletti; L Rumbach; G Coquillat; D Kurtz
Journal:  Epilepsia       Date:  1982-06       Impact factor: 5.864

10.  Effects of valproate and citrulline on ammonium-induced encephalopathy.

Authors:  J R Stephens; R H Levy
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.